Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Galectin Therapeutics Inc. (GALT)

Pharmaceutical Preparations

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240
NORCROSS, GA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/04/2002

Market Cap

144,485,192

Shares Outstanding

61,850,000

Weighted SO

61,848,657

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

MDGL --.--%

VKTX --.--%

SRPT --.--%

HEPA --.--%

PTCT --.--%

ICPT --.--%

TERN --.--%

AKRO --.--%

RETA --.--%

Beta

0.6340

Last Div

0.0000

Range

1.56-4.27

Chg

0.1300

Avg Vol

171633

Mkt Cap

144485192

Exch

NASDAQ

Country

US

Phone

678 620 3186

DCF Diff

3.0471

DCF

-0.7671

Div Yield

0.0000

P/S

1806.0649

EV Multiple

-5.3666

P/FV

-1.7576

Div Yield %

0.0000

P/E

-3.2603

PEG

1.0759

Payout

-0.0043

Current Ratio

1.8668

Quick Ratio

1.8668

Cash Ratio

1.7512

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

38564.8571

CCC

-38564.8571

Gross Margin

0.5625

Op Margin

-495.8250

Pretax Margin

-553.5625

Net Margin

-553.5625

Eff Tax Rate

0.0332

ROA

-1.6013

ROE

0.6701

ROCE

-3.0423

NI/EBT

1.0000

EBT/EBIT

1.1164

EBIT/Rev

-495.8250

Debt Ratio

3.3797

D/E

-1.1378

LT Debt/Cap

8.2864

Total Debt/Cap

8.2581

Int Coverage

-27.0758

CF/Debt

-0.3507

Equity Multi

-0.3367

Rec Turnover

0.0000

Pay Turnover

0.0095

Inv Turnover

0.0000

FA Turnover

2.2857

Asset Turnover

0.0029

OCF/Share

-0.5267

FCF/Share

-0.5267

Cash/Share

0.4113

OCF/Sales

-409.7125

FCF/OCF

1.0000

CF Coverage

-0.3507

ST Coverage

-744.9318

CapEx Coverage

0.0000

Div&CapEx Cov

-170.7135

P/BV

-1.7576

P/B

-1.7576

P/S

1806.0649

P/E

-3.2603

P/FCF

-4.4081

P/OCF

-4.4049

P/CF

-4.4049

PEG

1.0759

P/S

1806.0649

EV Multiple

-5.3666

P/FV

-1.7576

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 13, 08:45 UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Revenue Product Segmentation